ExodusPoint Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

ExodusPoint Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,443	Closed	-$97K	–	2021
2024 Q1	$97K	Buy	+18,443	New	+$88.7K	﹤0.01%	1417
2022 Q3	–	Sell	-1,205	Closed	-$32K	–	2339
2022 Q2	$32K	Sell	1,205 -1,080	-47%	-$38.1K	﹤0.01%	1830
2022 Q1	$85K	Buy	2,285 +1,885	+471%	+$82.2K	﹤0.01%	2022
2021 Q4	$23K	Buy	+400	New	+$26K	﹤0.01%	2080
2021 Q2	–	Sell	-10,702	Closed	-$684K	–	2849
2021 Q1	$684K	Buy	10,702 +3,001	+39%	+$200K	0.01%	1146
2020 Q4	$448K	Buy	+7,701	New	+$197K	﹤0.01%	1324

Other funds holding VTGN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ExodusPoint Capital Management's VTGN Position: Q2 2024 in Review

ExodusPoint Capital Management sold out of VistaGen Therapeutics (VTGN) in Q2 2024, closing a stake of 18,443 shares — an estimated $97K sold.

ExodusPoint Capital Management first reported a position in VTGN in Q4 2020 and held it in 6 quarters. The position peaked at $684K in Q1 2021. 43 funds tracked by Wall St. Rank hold VTGN as of Q2 2024.

ExodusPoint Capital Management reported no remaining VistaGen Therapeutics position as of Q2 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 18,443 VistaGen Therapeutics shares in Q2 2024, an estimated $97K.
ExodusPoint Capital Management first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 6 quarters.
ExodusPoint Capital Management's VistaGen Therapeutics position peaked at $684K in Q1 2021.
43 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.